Medical Oncology Unit, ICS Maugeri SpA SB-IRCCS, Pavia 27100, Italy.
University of Pavia, Ph.D. in Experimental Medicine, Pavia 27100, Italy.
Contrast Media Mol Imaging. 2019 Mar 26;2019:4325946. doi: 10.1155/2019/4325946. eCollection 2019.
The availability of new treatments for metastatic castrate-resistant prostate cancer (mCRPC) patients increases the need for reliable biomarkers to help clinicians to choose the better sequence strategy. The aim of the present retrospective and observational work is to investigate the prognostic value of F-fluorocholine (F-FCH) positron emission tomography (PET) parameters in mCRPC.
Between March 2013 and August 2016, 29 patients with mCRPC were included. They all received three-weekly docetaxel after androgen deprivation therapy, and they underwent F-FCH PET/computed tomography (CT) before and after the therapy. Semi-quantitative indices such as maximum standardized uptake value (SUV), mean standardized uptake value (SUV) with partial volume effect (PVC-SUV) correction, metabolically active tumour volume (MATV), and total lesion activity (TLA) with partial volume effect (PVC-TLA) correction were measured both in pre-treatment and post-treatment F-FCH PET/CT scans for each lesion. Whole-body indices were calculated as sum of values measured for each lesion (SSUV, SPVC-SUV, SMATV, and STLA). Progression-free survival (PFS) and overall survival (OS) were considered as clinical endpoints. Univariate and multivariate hazard ratios for whole-body F-FCH PET indices were performed, and < 0.05 was considered as significant.
Cox regression analysis showed a statistically significant correlation between PFS, SMATV, and STLA. No correlations between OS and F-FCH PET parameters were defined probably due to the small sample size.
Semi-quantitative indices such as SMATV and STLA at baseline have a prognostic role in patients treated with docetaxel for mCRPC, suggesting a potential role of F-FCH PET/CT imaging in clinical decision-making.
转移性去势抵抗性前列腺癌（mCRPC）患者新的治疗方法的出现增加了对可靠生物标志物的需求，以帮助临床医生选择更好的序贯策略。本回顾性观察性研究旨在探讨 F-氟代胆碱（F-FCH）正电子发射断层扫描（PET）参数在 mCRPC 中的预后价值。
2013 年 3 月至 2016 年 8 月期间，共纳入 29 例 mCRPC 患者。所有患者在去势治疗后均接受每周三次多西他赛治疗，并在治疗前后进行 F-FCH PET/CT 检查。对每个病灶的治疗前后 F-FCH PET/CT 扫描进行半定量指标（最大标准化摄取值[SUV]、部分容积效应校正后的平均 SUV[SUV]、代谢活跃肿瘤体积[MATV]和部分容积效应校正后的总病变活性[TLA]）测量。全身指标计算为每个病灶测量值的总和（SUV、PVC-SUV、MATV 和 PVC-TLA）。无进展生存期（PFS）和总生存期（OS）被认为是临床终点。对全身 F-FCH PET 指标进行单因素和多因素风险比分析，<0.05 为差异有统计学意义。
Cox 回归分析显示，PFS 与 SMATV 和 STLA 之间存在统计学显著相关性。由于样本量小，OS 与 F-FCH PET 参数之间未定义相关性。
基线时的半定量指标（如 SMATV 和 STLA）在接受多西他赛治疗的 mCRPC 患者中具有预后作用，提示 F-FCH PET/CT 成像在临床决策中可能具有一定作用。
